HOME >> BIOLOGY >> NEWS
Mutations in transporter protein shed light on neurodegenerative disorders

Bethesda, MD Researchers at Stanford University have made new discoveries that shed light on two inherited neurodegenerative disorders that are caused by inability of the body to transport sialic acid out of cellular compartments. The findings focus on how different mutations in one transporter molecule can cause a wide spectrum of symptoms in Salla Disease and infantile sialic acid storage disease (ISSD).

The research appears as the "Paper of the Week" in the January 14 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

The free sialic acid storage diseases are a range of rare, autosomal recessive, neurodegenerative disorders that result from the accumulation of sialic acid within lysosomes. There are two forms of the disease--Salla Disease, the milder form, and the more severe infantile sialic acid storage disease (ISSD).

"Clinically, these diseases consist of a spectrum," notes Dr. Richard J. Reimer of Stanford University. "In the severe phenotype infants are born with dysmorphic features, enlarged internal organs and die within a few months. With the milder disease the affected individuals have physical and mental developmental delay, but can live to adulthood."

In Salla Disease and ISSD, the amino sugar sialic acid accumulates in lysosomes, the cellular compartments that are responsible for degrading macromolecules. "Sialic acid is part of a number of proteins and normally it is removed from proteins as they are degraded in lysosomes," explains Dr. Reimer. "The free sialic acid is then released into the cytoplasm of the cell so that it can be reincorporated in to newly synthesized proteins. In Salla Disease and ISSD, the sialic acid is removed from the protein, but it is not released from the lysosome."

Genetic studies have shown that mutations in a single gene encoding a protein called sialin are responsible for both diseases. "The mil
'"/>

Contact: Nicole Kresge
nkresge@asbmb.org
301-634-7415
American Society for Biochemistry and Molecular Biology
7-Jan-2005


Page: 1 2

Related biology news :

1. Mutations point the way to new leukemia drugs
2. Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs
3. Mutations in NOTCH1 gene cause aortic valve disease
4. Mutations in transporter protein effect HDL levels in the general population
5. New study reveals structure of E. coli multidrug transporter protein
6. New measurements prove myosin VI can act as molecular transporter
7. New finding in studying dopamine transporter
8. Examining the serotonin transporter gene and family function
9. Penn researchers discover how key protein stops inflammation
10. UCF research links proteins, stem cells and potential Alzheimers treatment
11. Teamwork between 2 key proteins necessary for normal development and regulation of red blood cells

Post Your Comments:
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... Dr. Debra Auguste, associate professor, biomedical engineering, in ... College of New York, have identified a molecule ... of the most aggressive forms of breast cancer. ... high mortality rate owing to aggressive proliferation and ... However, Professor Auguste,s team, discovered the overexpression of ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:11/18/2014)... Array Architects is proud of a 30-year ... nation's hospitals and health systems. It is a niche ... careers to the advancement of both the healthcare and ... field, Laura Silvoy has been chosen to share her ... Conference. , Laura will present her Process Simulation ...
(Date:11/18/2014)... MENLO PARK, Calif. , Nov. 18, 2014 ... leading biotechnology company in the emerging field of ... clinical program, AST-OPC1 (oligodendrocyte progenitor cells) for complete ... as one of ten "Top Advanced Therapies Projects ... "We are delighted to receive this significant industry ...
(Date:11/18/2014)... , Nov. 18, 2014  Novira Therapeutics, Inc., a ... treatment of chronic hepatitis B virus (HBV) infection, today ... appointed to its Scientific Advisory Board (SAB).  ... SAB," said Christian S. Schade , Chief Executive ... development experience which will be invaluable to Novira as ...
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today the formation of a ... guidance to the Company as it advances the ... for the treatment of cutaneous T-cell lymphoma (CTCL), ...
Breaking Biology Technology:Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 2Asterias Biotherapeutics Named as a "Top Advanced Therapies Projects to Watch" and Will Present at the Therapeutic Area Partnerships Conference 3Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6
Cached News: